Supreme Court backs Oklahoma lethal injection drug; AbbVie expands in Ireland; Roche wins new EU nod for Perjeta;

@FiercePharma: Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug. FiercePharmaMarketing item | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: France's TxCell closes its plant at ANSM urging to avoid contamination. Story | Follow @EricPFierce

@CarlyHFierce: Can Allergan make double-chin drug pay off? Maybe, but slowly, analysts say. More | Follow @CarlyHFierce

> The U.S. Supreme Court said a drug used by Oklahoma in lethal injections, midazolam, does not violate a constitutional ban on cruel and unusual punishment. Report

> AbbVie ($ABBV) said it would expand its drug delivery facility in Sligo, Ireland, with 50 new jobs and a €40 million investment over four years. Release

> Roche's ($RHHBY) Perjeta won a European recommendation for use before surgery in women with HER2-positive breast cancer. Release

> Cost-effectiveness watchdogs in England bowed to pressure to reopen comments about new draft guidelines for treating diabetes, which have drawn considerable fire since the agency first unveiled them. Report

> Merck KGaA says it plans to add another 250 employees at Sigma-Aldrich ($SIAL) production sites in Israel as soon as its buyout of the devices company is approved by regulators. Report

> India-based Lupin says it's looking for alliances and "strategic brand acquisitions" to build up its business in the U.S. Report

> Samsung Bioepis said it's considering going public in the U.S. to raise money to develop more biosimilar drugs. Report

Medical Device News

@FierceMedDev: ICYMI: FDA gives nod to newest pelvic mesh product, despite ongoing safety issues. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Bard VP touts new study of its Lutonix drug-coated balloon to fight PAD. Article | Follow @VarunSaxena2

@EmilyWFierce: EU stands by crackdown on drug spending in Ireland. FiercePharma story | Follow @EmilyWFierce

> Former OtisMed CEO sentenced to two years in prison for shipping device after FDA rejected it. Article

> Olympus faces new suit from UCLA superbug patient over duodenoscope deviceFacing off rivals, Merck looks to expand CINV label on positive PhIII Emend study. Story

> Wearable, badge-based hand-washing monitoring system improves hospital staff compliance. Report

Biotech News

@FierceBiotech: Facing off rivals, Merck looks to expand CINV label on positive PhIII Emend study. Story | Follow @FierceBiotech

@JohnCFierce: These guys at Spinifex are smart--Giant Novartis downs a pain med in $200M-plus buyout of tiny Spinifex. More | Follow @JohnCFierce

@DamianFierce: From BIO last week, here's $QURE CEO Aldag talking about $CLDN, $AAVL and the future of gene therapy. Listen | Follow @DamianFierce

> AMAG snags Cord Blood Registry for $700M. Item

> Egalet's pain pill is tougher to abuse than Purdue's morphine tablet, study shows. Report

Animal Health News

> Egg prices soar, menu items dropped in wake of historic avian flu. More

> Investors erase Zoetis gains as questions emerge about Valeant's pursuit. Report

> Sorrento nabs key FDA designation for nonopiate drug to treat bone pain in dogs. Item

> Scottish scientists design piglets to resist African swine fever. Story

> Henry Schein expands global reach, taking majority stake in Denmark's Kruuse. Article

Biotech IT News

> Eisai strikes extensive multiyear IT outsourcing deal with Accenture. News

> Google steps up wearables plan with clinical trial-focused wristband. Story

> Analyst: R&D time pressures mean clinical trial tech and automation are finally taking off. More

> Google to pair its cloud-computing power with Broad's analytic tools. Article

> SEC starts pursuit of biotech-focused hacking ring. Report

Pharma Marketing News

> Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug. News

> Should Bristol-Myers cut payer deals to boost melanoma combo over one-drug treatments? More

> Will pharma jump into an EHR app store near you? Don't count on it anytime soon. Story

> Nuedexta maker Avanir taps actor Danny Glover to shed light on little-known neurological condition. Article

And Finally... As fears over dengue fever grow in Japan, sales of a mosquito-repelling fabric from Teijin Frontier have skyrocketed. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.